LIDDS AB (publ) (LIDDS.ST)
SEK 0.05
(-17.0%)
SEK 0.05
(-17.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -39.67 Million SEK | -11.31% |
| 2022 | -36.11 Million SEK | 1.88% |
| 2021 | -36.8 Million SEK | -15.6% |
| 2020 | -32.2 Million SEK | -78.76% |
| 2019 | -31.29 Million SEK | -598.66% |
| 2018 | -20.64 Million SEK | 61.77% |
| 2017 | -6.42 Million SEK | -0.52% |
| 2016 | 79.00 SEK | 15.12% |
| 2015 | -7.81 Million SEK | -12.83% |
| 2014 | -6.92 Million SEK | -75.79% |
| 2013 | -3.94 Million SEK | -7.81% |
| 2012 | -3.65 Million SEK | -2.24% |
| 2011 | -3.57 Million SEK | -95.46% |
| 2010 | -1.82 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.39 Million SEK | -499.0% |
| 2024 Q1 | -304 Thousand SEK | 103.23% |
| 2023 Q1 | -9.45 Million SEK | -8.29% |
| 2023 Q3 | -4.41 Million SEK | 39.28% |
| 2023 Q4 | -3.85 Million SEK | 12.58% |
| 2023 Q2 | -7.26 Million SEK | 23.16% |
| 2023 FY | - SEK | 32.71% |
| 2022 Q2 | -9.79 Million SEK | -1.63% |
| 2022 Q1 | -9.63 Million SEK | -10.9% |
| 2022 FY | - SEK | 1.88% |
| 2022 Q4 | -8.72 Million SEK | -9.65% |
| 2022 Q3 | -7.96 Million SEK | 18.69% |
| 2021 Q4 | -8.68 Million SEK | -12.64% |
| 2021 Q3 | -7.71 Million SEK | 20.39% |
| 2021 Q2 | -9.68 Million SEK | 9.62% |
| 2021 Q1 | -10.71 Million SEK | 12.15% |
| 2021 FY | - SEK | -15.6% |
| 2020 Q2 | -5.3 Million SEK | 32.49% |
| 2020 Q4 | -12.2 Million SEK | -88.11% |
| 2020 FY | - SEK | -78.76% |
| 2020 Q1 | -7.85 Million SEK | 48.17% |
| 2020 Q3 | -6.48 Million SEK | -22.37% |
| 2019 Q1 | -2.52 Million SEK | 47.72% |
| 2019 FY | - SEK | -598.66% |
| 2019 Q4 | -15.14 Million SEK | -447.8% |
| 2019 Q3 | -2.76 Million SEK | 18.0% |
| 2019 Q2 | -3.37 Million SEK | -33.54% |
| 2018 Q1 | -1.96 Million SEK | 10.61% |
| 2018 FY | - SEK | 61.77% |
| 2018 Q2 | -2.24 Million SEK | -14.26% |
| 2018 Q4 | -4.82 Million SEK | -191.28% |
| 2018 Q3 | 5.29 Million SEK | 335.78% |
| 2017 Q1 | -1.83 Million SEK | 13.32% |
| 2017 FY | - SEK | -0.52% |
| 2017 Q2 | -1.18 Million SEK | 35.45% |
| 2017 Q3 | -1.44 Million SEK | -21.74% |
| 2017 Q4 | -2.19 Million SEK | -52.05% |
| 2016 Q1 | -1.45 Million SEK | 8.72% |
| 2016 Q4 | -2.12 Million SEK | -32.11% |
| 2016 Q3 | -1.6 Million SEK | -10.84% |
| 2016 FY | - SEK | 15.12% |
| 2016 Q2 | -1.44 Million SEK | 0.55% |
| 2015 Q1 | -2.21 Million SEK | -25.9% |
| 2015 FY | - SEK | -12.83% |
| 2015 Q4 | -1.59 Million SEK | 12.1% |
| 2015 Q3 | -1.81 Million SEK | 17.0% |
| 2015 Q2 | -2.18 Million SEK | 1.22% |
| 2014 Q1 | -1.33 Million SEK | -22.03% |
| 2014 FY | - SEK | -75.79% |
| 2014 Q4 | -1.75 Million SEK | 6.47% |
| 2014 Q3 | -1.88 Million SEK | 3.59% |
| 2014 Q2 | -1.95 Million SEK | -46.25% |
| 2013 Q4 | -1.09 Million SEK | 16.8% |
| 2013 Q1 | -1.16 Million SEK | 0.0% |
| 2013 Q2 | -1.39 Million SEK | -19.52% |
| 2013 Q3 | -1.31 Million SEK | 5.87% |
| 2013 FY | - SEK | -7.81% |
| 2012 FY | - SEK | -2.24% |
| 2011 FY | - SEK | -95.46% |
| 2010 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Simris Alg AB (publ) | -22.36 Million SEK | -77.391% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 87.504% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 85.934% |
| Xintela AB (publ) | -53.47 Million SEK | 25.81% |
| Active Biotech AB (publ) | -43.88 Million SEK | 9.609% |
| Amniotics AB (publ) | -27.14 Million SEK | -46.152% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -179.032% |
| BioArctic AB (publ) | 275.38 Million SEK | 114.405% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 89.214% |
| Camurus AB (publ) | 562.54 Million SEK | 107.052% |
| Cantargia AB (publ) | -284.31 Million SEK | 86.047% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -102.615% |
| CombiGene AB (publ) | -35.33 Million SEK | -12.265% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 71.835% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -132.199% |
| Genovis AB (publ.) | 64.57 Million SEK | 161.435% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 65.476% |
| Mendus AB (publ) | -97.84 Million SEK | 59.457% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -7.147% |
| Intervacc AB (publ) | -68.98 Million SEK | 42.491% |
| Kancera AB (publ) | -61.88 Million SEK | 35.901% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -48.116% |
| Lipum AB (publ) | -37.11 Million SEK | -6.872% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -227.743% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 226.321% |
| NextCell Pharma AB | -40.98 Million SEK | 3.209% |
| OncoZenge AB (publ) | 7.26 Million SEK | 645.968% |
| Saniona AB (publ) | -69.69 Million SEK | 43.081% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 76.639% |
| Ziccum AB (publ) | -20.34 Million SEK | -95.015% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 1983600.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 83.305% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -1807.212% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -195.361% |
| Corline Biomedical AB | -1.69 Million SEK | -2245.949% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 77.112% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 27.617% |
| Aptahem AB (publ) | -10 Million SEK | -296.334% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 443.493% |
| Fluicell AB (publ) | -25.91 Million SEK | -53.083% |
| Biovica International AB (publ) | -119.5 Million SEK | 66.805% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 6.049% |
| AcouSort AB (publ) | -16.7 Million SEK | -137.502% |
| Abliva AB (publ) | -93.6 Million SEK | 57.621% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 87.568% |
| 2cureX AB (publ) | -35.13 Million SEK | -12.904% |
| I-Tech AB | 30.34 Million SEK | 230.73% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 94.448% |
| Cyxone AB (publ) | -20.41 Million SEK | -94.327% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 61.28% |
| Biosergen AB | 228 Thousand SEK | 17499.123% |
| Nanologica AB (publ) | -62.11 Million SEK | 36.139% |
| SynAct Pharma AB | -222.7 Million SEK | 82.187% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 9.555% |
| BioInvent International AB (publ) | -312.7 Million SEK | 87.314% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 12921.051% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 94554.63% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 82.873% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -350.157% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 63.457% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -245.889% |